# Danaher Corporation (DHR)

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-12  
**Report type:** Primer (steps 1–3 of 19)  
**API endpoint:** GET /api/v1/research/DHR/primer

## Business Model

---
ticker: DHR
step: 01
generated: 2026-05-12
source: quick-research
---

### Danaher Corporation (DHR) — Business Overview

#### Business Description
Danaher is a leading global designer + manufacturer of high-quality scientific instruments and consumables across three segments: Biotechnology (Cytiva + Pall — bioprocessing), Life Sciences (Leica Microsystems, SCIEX — research instruments), and Diagnostics (Beckman Coulter, Cepheid — clinical lab + molecular). Powered by the Danaher Business System (DBS), the proprietary continuous improvement methodology. CEO Rainer Blair has been in the role since September 2020. In September 2023, Danaher spun off Environmental & Applied Solutions as Veralto. Pending $9.9B Masimo acquisition adds connected medical devices.

#### Revenue Model
- **Biotechnology (~40% of revenue):** Bioprocessing consumables + equipment via Cytiva (acquired 2020 GE Biosciences for $21B) + Pall — supports biologic drug manufacturing, vaccines, cell/gene therapy
- **Diagnostics (~35%):** Clinical lab instruments (Beckman Coulter) + point-of-care molecular (Cepheid)
- **Life Sciences (~25%):** Microscopy (Leica), mass spectrometry (SCIEX), liquid handling (Beckman Coulter), centrifugation
- ~75-80% recurring revenue (consumables + services) — exceptional for industrial conglomerate

#### Products & Services

##### Biotechnology (Cytiva + Pall)
- **Bioprocessing consumables:** Bioreactors, filters, chromatography resins, single-use technologies
- **Cytiva-branded equipment + AKTA chromatography systems**
- **Pall filtration:** Industrial + biopharma filtration
- 75% of Cytiva exposure is monoclonal antibody (mAb) production

##### Diagnostics
- **Cepheid:** GeneXpert PCR system + cartridges — respiratory, GI, HIV, TB, oncology
- **Cepheid Xpert GI Panel (new FDA clearance):** 11-pathogen GI test
- **Beckman Coulter Diagnostics:** Hematology, urinalysis, chemistry, immunoassay
- **Radiometer:** Blood gas analyzers
- **HemoCue:** Point-of-care testing

##### Life Sciences
- **Leica Microsystems:** Light + electron microscopes, slides scanners
- **SCIEX:** Mass spectrometry, capillary electrophoresis
- **Beckman Coulter Life Sciences:** Flow cytometry, centrifugation, liquid handling
- **Phenomenex:** Chromatography consumables
- **IDT (Integrated DNA Technologies):** Custom DNA synthesis

##### Pending Acquisitions
- **Masimo (announced 2026):** $9.9B for connected medical devices — concerning to bears on "diworsification"

#### Customer Base & Go-to-Market
- **Biopharma + Pharma manufacturers:** Top global biopharma companies for bioprocessing
- **Hospitals + clinical labs:** Diagnostics products
- **Academic + government research:** Life Sciences instruments
- **Customer concentration:** Top 10 customers ~20% of revenue (diversified)
- **Geographic mix:** ~45% NA, ~30% Europe, ~25% APAC (China specifically ~10%; weak in 2024-2025 due to VBP)

#### Competitive Position
Danaher has #1 or #2 positions in most addressable markets: #1 bioprocessing (Cytiva ~25% market share, ahead of Sartorius + Thermo Fisher in some sub-segments), #1 point-of-care molecular diagnostics (Cepheid), top-3 in clinical chemistry (Beckman Coulter). Moats: (1) DBS continuous improvement = sustained margin expansion, (2) bioprocessing consumables "razor-and-blade" recurring revenue, (3) Cepheid installed base + cartridge stickiness, (4) capital allocation track record. Competitors: Sartorius (bioprocessing), Thermo Fisher Scientific (broad), Agilent (life sciences instruments), Roche Diagnostics (clinical).

#### Key Facts
- Founded: 1969 (originally a real estate investment trust); acquired/transformed into industrial conglomerate via DBS
- Headquarters: Washington, DC
- Employees: ~63,000
- Exchange: NYSE
- Sector / Industry: Health Care / Life Sciences Tools & Services
- Market Cap: ~$155B (May 2026)
- CEO: Rainer M. Blair (since September 2020)
- Chairman: Mitchell P. Rales (co-founder)
- Dividend: $1.16 annual ($0.29 quarterly)
- Recent: Veralto spin-off (Sept 2023); pending Masimo acquisition $9.9B

## Financial Snapshot

---
ticker: DHR
step: 04
generated: 2026-05-12
source: quick-research
---

### Danaher Corporation (DHR) — Financial Snapshot

#### Income Statement Summary (post-Veralto spin-off Sept 2023)

| Metric | FY2023 | FY2024 | FY2025 | YoY |
|--------|--------|--------|--------|-----|
| Revenue | $23.9B | $23.9B | $24.6B | +3% |
| Non-GAAP Core Revenue Growth | -3% | flat | +2% | recovering |
| Non-GAAP Gross Margin | 60% | 60% | 60% | stable |
| Non-GAAP Operating Margin | 27% | 26% | 27% | recovering |
| Non-GAAP Adj. EPS | $7.58 | $7.46 | $7.80 | +5% |
| Free Cash Flow | $7.6B | ~$5.5B | $5.3B | -4% |

#### Segment Performance (FY2025)

| Segment | Revenue | Growth |
|---------|---------|--------|
| Biotechnology | ~$10B | +mid-single-digit (bioprocessing recovering) |
| Diagnostics | ~$8.5B | -low-single-digit (China VBP drag, COVID rolloff) |
| Life Sciences | ~$6.1B | flat |

#### Q1 2026 Highlights

| Metric | Q1 2026 | YoY |
|--------|---------|-----|
| Revenue | $6.0B | flat |
| Core Revenue Growth | +0.5% | |
| Bioprocessing Equipment Orders | +30%+ YoY | FIRST POSITIVE GROWTH IN ~2 YEARS |
| FCF Conversion | 146% | |
| Bioprocessing Consumables Growth | low double-digit | |

#### Key Product Detail

| Product | FY2025 Notes |
|---------|--------------|
| Cytiva (bioprocessing) | Equipment order recovery; consumables strong |
| Cepheid respiratory | ~$1.7B target FY26 (normal endemic season) |
| Cepheid GI Panel | New FDA clearance — growth vector |
| China Diagnostics | -high-single-digit; VBP $150M FY headwind |

#### Cash Flow & Balance Sheet (FY2025)

| Metric | Value |
|--------|-------|
| Operating Cash Flow | ~$6.5B |
| Capital Expenditures | ~$1.2B |
| Free Cash Flow | $5.3B |
| Cash & Investments | ~$3B |
| Total Debt | ~$20B (pre-Masimo) |
| Net Debt/EBITDA | ~2.0x (pre-Masimo) |

#### Key Ratios (approximate, May 2026)
- P/E (forward): ~27x | EV/EBITDA: ~17x | Dividend Yield: ~0.6%
- ROIC: ~10% (pre-Masimo)
- FCF margin: ~22%

#### Growth Profile
Q1 2026 marked an inflection: bioprocessing equipment orders +30% YoY (first positive in nearly 2 years). Consumables low double-digit growth. Management raised FY26 EPS guidance on bioprocessing momentum. Q1 FCF conversion 146% — exceptional. Bear case "bioprocessing winter" appears to be ending. Diagnostics still drag (China VBP, normalized respiratory).

#### Forward Estimates
- **FY2026E Revenue:** ~$26B (+5-6%)
- **FY2026E Adj EPS:** ~$8.50 (+9%)
- **FY2027E EPS:** ~$9.50 (+12%)
- **FY2026 Bioprocessing core growth:** high-single-digit (mgmt guide)
- **Long-term EPS growth target:** 10-12%

#### Capital Return
- Dividend $1.16 annual (~$0.9B paid)
- Buybacks: $5-7B annual run rate (varies with M&A)
- Total return ~3-5%
- Masimo pending $9.9B acquisition will constrain near-term buybacks

## Recent Catalysts

---
ticker: DHR
step: 12
generated: 2026-05-12
source: quick-research
---

### Danaher Corporation (DHR) — Investment Catalysts & Risks

#### Bull Case Drivers

1. **Bioprocessing inflection — equipment orders +30% YoY** — Q1 2026 marked the first quarter of positive YoY equipment order growth in nearly 2 years. Consumables low double-digit growth. Management raised FY26 EPS guidance on this momentum. Bears called this the "bioprocessing winter" — that winter is ending, and management guides high-single-digit core growth in bioprocessing for FY26.

2. **mAb production scale = durable consumables tailwind** — 75% of Cytiva exposure is monoclonal antibody (mAb) manufacturing. Global mAb production continues compounding as more biologics are approved (immunology, oncology, cardiovascular). Consumables follow installed bioreactor capacity — multi-year recurring revenue secular tailwind.

3. **Cepheid + diagnostics resilient** — Cepheid GI Panel new FDA clearance opens new market. Cepheid respiratory targeting $1.7B FY26. While China VBP and lower COVID create near-term drag, the underlying franchise is stable. Free cash flow conversion at 146% in Q1 2026 shows operating leverage even at modest growth.

4. **DBS continuous improvement + capital allocation** — Danaher Business System has driven decades of margin expansion + ROIC. Track record of accretive M&A (GE Biosciences/Cytiva $21B, Pall, Beckman Coulter, Cepheid). 146% FCF conversion + $5.3B FCF base allows continued capital deployment.

#### Bear Case Risks

1. **Masimo "diworsification" risk** — $9.9B Masimo acquisition (announced 2026) is bear concern. Masimo is connected medical devices — somewhat outside Danaher's core bioprocessing/diagnostics/life sciences. Bears worry Danaher is "buying revenue" to offset slow bioprocessing recovery. Integration + valuation discipline questions.

2. **NIH funding uncertainty + academic weakness** — Management cited US funding uncertainty (especially academic/university research) as weakening Life Sciences outlook. Continued reductions in NIH + university research funding under Trump administration could materially impact Leica + SCIEX academic exposure.

3. **China VBP drag + Diagnostics weakness** — China Diagnostics core revenue down high-single-digit. China VBP impact accelerated to $150M annual (vs prior $50M expectation). If VBP expands to additional Cepheid + Beckman Coulter categories, headwind expands materially.

4. **Stock -24% in 2026, -4% TTM** — DHR fell ~24% in 2026 YTD on bioprocessing winter concerns + Masimo concerns. While Q1 marked inflection, bears note that stock has been falling for several years despite "biological engine" thesis. If bioprocessing recovery proves shallow, multiple compression continues.

#### Upcoming Events

- **Q2 2026 earnings (July 2026)** — Bioprocessing order growth durability test; Masimo deal commentary
- **Q3 2026 earnings (October 2026)** — Diagnostics recovery (Cepheid respiratory season); China outlook
- **Masimo deal close** — Expected mid-to-late 2026
- **Cepheid GI Panel commercial ramp** — New product launch metrics
- **Bioprocessing capacity additions at customers** — Drives Cytiva equipment orders

#### Analyst Sentiment

Sell-side consensus is **Hold / Moderate Buy** with average price targets in the $230-260 range vs. recent ~$215 trading levels (~7-21% upside). Bulls (Insider Monkey, Simply Wall St "biological engine") cite bioprocessing inflection + Q1 momentum + DBS. Bears focus on Masimo integration + NIH funding. Stock has underperformed peers (TMO, ABT) over past 2 years — bioprocessing recovery is the swing factor for re-rating.

#### Research Date
Generated: 2026-05-12

## Full Research Available

This primer covers steps 1–3 of 19. The full deep dive (moat analysis, DCF, bull/bear,
management quality, earnings transcript analysis) is available via:

- Investment memo: /memo/dhr
- Full research API: GET /api/v1/research/DHR/memo
- Coverage universe: /stocks